The Asia Pacific Epigenetics Market is expected to witness market growth of 15.2% CAGR during the forecast period (2022-2028).
DNA methylation, histone methylation, and acetone methylation are some of the most common epigenetic technologies. Strong correlations between DNA methylation and aging have been discovered through research. The International Human Epigenome Consortium, the National Cancer Institute (NCI), and the National Institute of Health (NIH) are all affecting the market in a good way by providing financial support for epigenetics research and development. Moreover, the growing emphasis on studying epigenetic changes at the genetic and molecular level, as well as the development of epigenetics-based medicinal treatments, is likely to have a favorable impact on research funding.
The epigenetics market is primarily driven by technological breakthroughs in the field of epigenetics. In comparison to typical microarrays, epigenetics-based assays are extremely useful and advantageous due to advantages such as the requirement for a low concentration of input material and the lack of experimental bias in microarrays. Advanced epigenetic tools and sequencing platforms have been the subject of research.
Major trends in the APAC region are increased awareness of epigenetics, increased penetration of important players in growing Asia-Pacific countries, and expansion of research and clinical infrastructure. Due to increased disposable income, significant unmet clinical requirements of patients, rising knowledge of early diagnosis, and availability of efficient treatment in emerging nations such as India and China, the market is likely to flourish in the upcoming years. In addition, an increase in instances of various types of malignancies in this region is the prominent growth catalyst for the regional market.
Moreover, the regional market has witnessed increased disposable income, significant unmet clinical needs of patients, growing awareness of early diagnosis, and availability of suitable treatment in emerging nations such as India and China. Because of the increased cases of various forms of malignancies in this region, Asia Pacific is the most promising region for industry players. Market growth is expected to be aided by the growing geriatric population.
The China market dominated the Asia Pacific Epigenetics Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $232.4 Million by 2028. The Japan market is anticipated to grow at a CAGR of 14.5% during (2022-2028). Additionally, The India market is expected to showcase a CAGR of 15.9% during (2022-2028).
Based on Application, the market is segmented into Oncology and Non-Oncology. Based on Product, the market is segmented into Kits, Reagents, Enzymes, and Instruments. Based on End User , the market is segmented into Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, and Contract Research Organizations. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Abcam plc, Agilent Technologies, Inc., Hologic, Inc., Illumina, Inc., Merck Group, PerkinElmer, Inc., Qiagen N.V., Thermo Fisher Scientific, Inc., Zymo Research, and Active Motif, Inc.
By Application
By Country
DNA methylation, histone methylation, and acetone methylation are some of the most common epigenetic technologies. Strong correlations between DNA methylation and aging have been discovered through research. The International Human Epigenome Consortium, the National Cancer Institute (NCI), and the National Institute of Health (NIH) are all affecting the market in a good way by providing financial support for epigenetics research and development. Moreover, the growing emphasis on studying epigenetic changes at the genetic and molecular level, as well as the development of epigenetics-based medicinal treatments, is likely to have a favorable impact on research funding.
The epigenetics market is primarily driven by technological breakthroughs in the field of epigenetics. In comparison to typical microarrays, epigenetics-based assays are extremely useful and advantageous due to advantages such as the requirement for a low concentration of input material and the lack of experimental bias in microarrays. Advanced epigenetic tools and sequencing platforms have been the subject of research.
Major trends in the APAC region are increased awareness of epigenetics, increased penetration of important players in growing Asia-Pacific countries, and expansion of research and clinical infrastructure. Due to increased disposable income, significant unmet clinical requirements of patients, rising knowledge of early diagnosis, and availability of efficient treatment in emerging nations such as India and China, the market is likely to flourish in the upcoming years. In addition, an increase in instances of various types of malignancies in this region is the prominent growth catalyst for the regional market.
Moreover, the regional market has witnessed increased disposable income, significant unmet clinical needs of patients, growing awareness of early diagnosis, and availability of suitable treatment in emerging nations such as India and China. Because of the increased cases of various forms of malignancies in this region, Asia Pacific is the most promising region for industry players. Market growth is expected to be aided by the growing geriatric population.
The China market dominated the Asia Pacific Epigenetics Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $232.4 Million by 2028. The Japan market is anticipated to grow at a CAGR of 14.5% during (2022-2028). Additionally, The India market is expected to showcase a CAGR of 15.9% during (2022-2028).
Based on Application, the market is segmented into Oncology and Non-Oncology. Based on Product, the market is segmented into Kits, Reagents, Enzymes, and Instruments. Based on End User , the market is segmented into Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, and Contract Research Organizations. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Abcam plc, Agilent Technologies, Inc., Hologic, Inc., Illumina, Inc., Merck Group, PerkinElmer, Inc., Qiagen N.V., Thermo Fisher Scientific, Inc., Zymo Research, and Active Motif, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Application
- Oncology
- Non-Oncology
- Kits
- Reagents
- Enzymes
- Instruments
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
- Contract Research Organizations
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Abcam plc
- Agilent Technologies, Inc.
- Hologic, Inc.
- Illumina, Inc.
- Merck Group
- PerkinElmer, Inc.
- Qiagen N.V.
- Thermo Fisher Scientific, Inc.
- Zymo Research
- Active Motif, Inc.
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. Asia Pacific Epigenetics Market by Application
Chapter 5. Asia Pacific Epigenetics Market by Product
Chapter 6. Asia Pacific Epigenetics Market by End User
Chapter 7. Asia Pacific Epigenetics Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Abcam plc
- Agilent Technologies, Inc.
- Hologic, Inc.
- Illumina, Inc.
- Merck Group
- PerkinElmer, Inc.
- Qiagen N.V.
- Thermo Fisher Scientific, Inc.
- Zymo Research
- Active Motif, Inc.
Methodology
LOADING...
